Lilly’s new investments are expected to create approximately 100 skilled manufacturing jobs at the Indianapolis facilities
Eli Lilly and Company's Corporate Center in Indianapolis, Indiana, US (Credit: Momoneymoproblemz/Wikipedia)
Eli Lilly and Company (Lilly) has announced plans to invest $400m in its manufacturing facilities at Lilly Technology Centre campus in Indianapolis, Indiana, US.
Lilly said that the increasing demand for its medicines has driven the investment decision, which is set to provide additional manufacturing capacity for future medicines from its pipeline.
Chairman and chief executive officer David Ricks said: “These investments demonstrate Lilly’s commitment to our manufacturing footprint in Indiana and the United States, and have been made possible by the tax reform measures passed by Congress in 2017.
“With more capital available as a result of tax reform, Lilly and other Indiana companies are able to re-invest and expand production here at home. This is crucial for us to continue to advance our state’s economy and drive future investment – adding high-tech jobs and facilities that keep Indiana competitive in the global marketplace.”
The investment will enhance production of insulin and diabetes medicines
Lilly said that the new investments include enhancements to existing manufacturing facilities producing insulin, additional capacity for its portfolio of diabetes medicines and initial capital investments for new medicines.
In addition to increasing the capacity and capabilities of the facilities, the new investments are also expected to create approximately 100 skilled manufacturing jobs at the Indianapolis facilities.
The company claims that since 2012, it has invested more than $5bn in the US and approximately $2bn in manufacturing of diabetes medicines.
Lilly senior vice president and president of manufacturing operations Myles O’Neill said: “These investments support our manufacturing capabilities in Indianapolis, including additional capacity and technology upgrades to our active ingredient, syringe filling, device assembly and packaging operations.
“All of these projects support Lilly’s investment in next-generation manufacturing and feature high levels of automation, robotics, new technologies and advanced data analytics. To make medicine, we need highly skilled technicians, scientists, and engineers, who are economic catalysts for local communities.”